Predictive value of high titer of GAD65 antibodies in a case of limbic encephalitis

We report the case of a 42-year-old woman who presented with vertigo and migraine and rapidly developed cognitive decline and seizures. Both serum and cerebro-spinal fluid samples showed high titer of anti-glutamic acid decarboxylase (anti-GAD65) antibodies (998,881 IU/ml and 54,687 IU/ml respective...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimmunology 2019-12, Vol.337, p.577063-577063, Article 577063
Main Authors: Di Giacomo, Roberta, Deleo, Francesco, Pastori, Chiara, Didato, Giuseppe, Andreetta, Francesca, Del Sole, Angelo, de Curtis, Marco, Villani, Flavio
Format: Article
Language:English
Subjects:
Anti-glutamic acid decarboxylase 65 antibody
Autoimmune encephalitis
Immunotherapy
Limbic encephalitis
Neuroimmunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the case of a 42-year-old woman who presented with vertigo and migraine and rapidly developed cognitive decline and seizures. Both serum and cerebro-spinal fluid samples showed high titer of anti-glutamic acid decarboxylase (anti-GAD65) antibodies (998,881 IU/ml and 54,687 IU/ml respectively). Limbic encephalitis was diagnosed and high dose steroids treatment started. During one-year follow-up, without further immunomodulatory therapy, the patient became seizure free, and cognitive functions returned to normal. Serum anti-GAD65 antibodies titer decreased significantly but remained elevated (192,680 IU/ml). We discuss the prognostic and pathogenic value of high titer anti-GAD65 antibodies and its variations in a case of autoimmune limbic encephalitis. [Display omitted] •Clinical spectrum of anti-GAD65 antibodies extended from asymptomatic to fulminant encephalitis.•Pathogenic link between the antibodies and limbic encephalitis appeared not clear•Antibodies titers may not be an indicator to guide long-term immunotherapy.•Narrow clinical and laboratory follow-up was relevant to therapeutic management.•Early treatment enabled good outcome in otherwise hard-to-treat condition.
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2019.577063